[Tumor heterogeneity and drug resistance of targeted antitumor agents]
Abstract:
The popular application of targeted antitumor agents has greatly improved the efficacies of tumor therapy. However, some patients develop drug resistance after the administration with them for six to twelve months, leading to the failure of treatment. The cause of it is mainly due to tumor heterogeneity. The genesis of tumor heterogeneity is closely associated with tumor stem cells, genetic instability, cell competition and stochastic events. There are a lot of mechanisms involved in the drug resistance to the targeted agents. Tumor heterogeneity and drug resistance are great challenges for precision oncology and are taken account for the process of research and development of new antitumor agents.
Insights
Targeted antitumor agents show promise but often fail due to tumor heterogeneity, a major challenge in cancer therapy. Understanding this resistance is key to developing new, effective cancer treatments.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Targeted antitumor agents have improved cancer therapy efficacy.
- Drug resistance develops in patients after 6-12 months, causing treatment failure.
- Tumor heterogeneity is a primary cause of this acquired resistance.
Purpose of the Study:
- To explore the mechanisms of drug resistance in cancer therapy.
- To understand the role of tumor heterogeneity in treatment failure.
- To identify challenges and research directions for developing new antitumor agents.
Main Methods:
- Literature review on tumor heterogeneity and drug resistance mechanisms.
- Analysis of factors contributing to the genesis of tumor heterogeneity (e.g., tumor stem cells, genetic instability).
- Examination of various drug resistance mechanisms against targeted agents.
Main Results:
- Tumor heterogeneity arises from factors including tumor stem cells, genetic instability, cell competition, and stochastic events.
- Multiple mechanisms contribute to the development of drug resistance to targeted therapies.
- Tumor heterogeneity and drug resistance pose significant challenges to precision oncology.
Conclusions:
- Tumor heterogeneity is a critical factor driving drug resistance in targeted cancer therapy.
- Addressing tumor heterogeneity and resistance mechanisms is essential for advancing new antitumor agent development.
- Overcoming these challenges is vital for the future of precision oncology.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:26Heart Failure Drugs: Inotropic Agents
01:21Antipsychotic Drugs: Typical and Atypical Agents
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents